Technologies
PDF


WARF: P150262US03

Reagents for Bioreversible Protein Esterification


INVENTORS -

Ronald Raines, Kalie Mix

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a potentially best-in-class diazo compound for esterification of biological molecules.
OVERVIEWChemoselective transformations are of key importance in modern chemical biology. Protein esterification can, for example, be employed for labeling, enhanced cellular uptake and other useful protein modifications. For this reason methods and reagents for selective esterification of carboxyl groups in proteins/polypeptides are of particular interest, especially if the reactions can be carried out in buffered aqueous solution and do not require a catalyst.

While there has been some success in this space, there remains a need for more efficient chemoselective esterification reagents for proteins and other biological molecules (e.g., nucleic acids) that result in high-yield, bioreversible ester formation. Such reagents should be synthetically amenable to modification with biologically useful entities.
THE INVENTIONUW–Madison researchers have developed an optimized diazo compound, derived from phenylglycine amide, for converting carboxylate groups into an ester in high yield in buffered water. The ensuing esters are labile to esterase enzymes such as reside in all human cells, making the modification bioreversible. The novel compound is small, avoids deleterious side reactions and has a modularity that enables broad utility.
APPLICATIONS
  • Reagent market
  • Potential biomedical utility; promoting cellular uptake of cargo molecules
KEY BENEFITS
  • Provides high esterification rates and yields
  • Bioreversible
  • Compound is novel, small and modular.
  • Broad utility
STAGE OF DEVELOPMENTThe novel compound (R1(R2)C=N=N) is markedly superior to other reagents in esterifying a model protein in a bioreversible manner. The R’ group may be virtually any moiety, including ones that promote cellular uptake, cancer-cell targeting and enhanced pharmacokinetics (e.g., PEG). All of these moieties would be removed from the protein by cellular esterases.
Contact Information
For current licensing status, please contact Jennifer Gottwald at jennifer@warf.org or 608-960-9854.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.